Want to join the conversation?
$CRL's agreement to acquire WIL Research is also expected to add $240-250MM to $CRL's 2017 consolidated revenue and expected to be accretive to non-GAAP EPS by at least $0.20 in 2016 and $0.45-0.50 in 2017. The company expects to generate operational synergies from the acquisition, with benefits totaling $17-20MM within two years of closing.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.